DOCSLIB.ORG

Driving Transformation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Driving Transformation 2020 ANNUAL REPORT TELEFLEX | 2020 ANNUAL REPORT Driving Transformation GROWTH INNOVATION OUTCOMES CORPORATE HEADQUARTERS 550 E. Swedesford Road, Suite 400, Wayne, PA 19087 610.225.6800 | www.teleflex.com 3 | 2020 TELEFLEX ANNUAL REPORT BOARD OF DIRECTORS Karen Boylan Kevin Robinson Dividend Reinvestment Listed in Order of Tenure Corporate Vice President, Vice President and General Teleflex Incorporated offers a Global Strategic Projects Manager, Anesthesia and dividend reinvestment and direct Financial Highlights George Babich, Jr.*1 Emergency Medicine stock purchase and sale plan. Retired President and Gwen Chapman For enrollment information, Chief Executive Officer Corporate Vice President and Greg Stotts please contact American Stock Checkpoint Systems, Inc. Chief Compliance Officer Vice President and Transfer & Trust Company, General Manager, OEM FROM CONTINUING OPERATIONS (Dollars in millions, except per share data) Lead Director John Deren Dividend Reinvestment Department, Compensation Committee Chair Vice President and Ed Weidner 1-877-842-1572 (toll free). Stephen K. Klasko, M.D.*2 Chief Accounting Officer Vice President, Customer Code of Ethics and Experience and Commercial $119,747 $2,595,362 President and CEO Business Guidelines $2,537,156 Michael DiGiuseppe Operations $113,857 $2,448,383 Thomas Jefferson University Vice President and All Teleflex businesses around $106,208 and Jefferson Health General Manager, Jay White the world share a common Code $2,146,303 Stuart A. Randle*1, 2 Respiratory Division and Corporate Vice President and of Ethics, which guides the way $84,770 we conduct business. The Code is 2020 Retired Chief Executive Officer Corporate Accounts President, Global Commercial available on the Teleflex website Net Revenues Ivenix, Inc. Timothy Duffy Mario Wijker at www.teleflex.com. by Reporting Nominating and Governance Vice President and Corporate Vice President, Quality Segment Commitee Chair Chief Information Officer Assurance and Regulatory Affairs Certifications Candace H. Duncan*3 The certifications by the Chief Jake Elguicze James Winters Executive Officer and the Chief Retired Managing Partner Treasurer and Vice President, Corporate Vice President, Financial Officer of Teleflex KPMG LLP Investor Relations Manufacturing and Supply Chain Incorporated required under 17 18 19 20 17 18 19 20 Audit Committee Chair James Ferguson Section 302 of the Sarbanes-Oxley *3 Gretchen R. Haggerty President and General Manager, INVESTOR INFORMATION Act of 2002 have been filed as Retired Executive Vice President Surgical and Latin America Teleflex Incorporated exhibits to Teleflex Incorporated’s Europe, and Chief Financial Officer 2020 Annual Report on Form 550 East Swedesford Road Research and Middle East Asia United States Steel Corp. Michelle Fox 10-K. In addition, in May 2020, Wayne, Pennsylvania 19087 Net Revenues Development Americas and Africa Pacific OEM Corporate Vice President and the Chief Executive Officer of Richard A. Packer*2 Chief Medical Officer Investor Information Teleflex Incorporated certified Primary Executive Director Sunny Goh Market and ownership to the New York Stock Exchange (2.2%) 5.2% 58% 23% 10% 9% Asahi Kasei (“NYSE”) that he is not aware President, APAC of common stock: Variance Variance Andrew A. Krakauer*1 New York Stock Exchange of any violation by the Company Retired Chief Executive Officer Marie Hendrixson Trading symbol: TFX of NYSE corporate governance Cantel Medical Corp. Vice President, listing standards, as required by Internal Audit Investor Relations Section 303A.12(a) of the NYSE $437,143 $11.15 $437,068 Liam J. Kelly Investors, analysts, and others Corporate Governance Rules. $10.67 Chairman, President and Cameron Hicks seeking information about the $9.90 $435,086 Chief Executive Officer Corporate Vice President, company should contact: Independent Registered Teleflex Incorporated Human Resources and Jake Elguicze Public Accounting Firm $8.40 Communications PricewaterhouseCoopers LLP 2020 John C. Heinmiller*3 Teleflex Incorporated (610) 948-2836 Philadelphia, Pennsylvania Net Revenues Retired Executive Vice President Matthew James [email protected] and Chief Financial Officer President, EMEA Forward-Looking by End Market www.teleflex.com St. Jude Medical and Global Urology $426,301 Statements A copy of the Annual Report as filed *Board Committees In accordance with the safe Michael Kryukov with the Securities and Exchange 1 Compensation harbor provisions of the Private Vice President, Tax Commission on Form 10-K, interim 2 Nominating and Governance Securities Litigation Reform Act of Bert Lane reports on Form 10-Q, and current 1995, the company notes that certain 17 18 19 20 17 18 19 20 3 Audit Vice President, reports on Form 8-K can be accessed statements contained in this report on the Investor page of the EXECUTIVE LEADERSHIP Global Logistics and Distribution are forward-looking in nature. These company’s website or can be mailed forward-looking statements include Net Cash Provided Hospitals/ Medical Liam J. Kelly Daniel V. Logue upon request. matters such as business strategies, Corporate Vice President, Adjusted Earnings by Operating Healthcare Device Home Chairman, President and market potential, product deployment, 1 General Counsel and Secretary Transfer Agent and Registrar Per Share Activities Providers Manufacturers Care Chief Executive Officer Questions concerning transfer future financial performance, and other future-oriented matters. Such Thomas E. Powell Jake Newman requirements, lost certificates, Group President, matters inherently involve many risks (4.3%) 0.0% 88% 9% 3% Executive Vice President and dividends, duplicate mailings, Interventional and Vascular change of address, or other and uncertainties. For additional Variance Variance Chief Financial Officer information, please refer to the Daniel Price stockholder matters should be Petro Barchuk addressed to: company’s Securities and Exchange Vice President, Vice President, Commission filings and the Form Commercial Finance American Stock Transfer 10-K included in the Annual Report. Financial Planning and Analysis & Trust Company Tyler Binney 6201 15th Ave President and General Manager, Brooklyn, New York 11219 Interventional Urology (800) 937-5449 (toll free) ¹ A table reconciling adjusted earnings per share to the most directly comparable GAAP measure can be found at the end of this Annual Report. Teleflex, the Teleflex logo, and each of the other brand and product names referenced herein are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Driving Transformation Leveraging Our Portfolio As the global healthcare market evolves, Teleflex is driving transformation across every facet of The Teleflex product portfolio our business — from expanding into key clinical comprises many trusted names markets and high-growth global regions, to in medical technology, including innovating differentiated products that can improve Arrow®, Deknatel®, Hudson RCI®, patient outcomes, reduce healthcare costs, and LMA®, Pilling®, Rüsch®, UroLift®, create efficiencies. As we enter 2021, we continue QuikClot®, and Weck®. Each of these our journey from a medium-growth company brands has its own unique position with margin expansion to a high-growth company within its market niche, and together with margin expansion, delivering strong and they share a common purpose: To consistent value for our shareholders, customers, leverage best-in-class technologies and employees. to enable effective clinical solutions for patients and healthcare providers around the world. GROWTH We are driving sustainable, long-term growth across our products, margins, and markets, and we are creating new expansion opportunities for our global constituents. INNOVATION We are bringing advanced medical devices to key clinical markets and high-growth regions around the globe. OUTCOMES We are collaborating with our customers to create effective solutions that improve health outcomes, create efficiencies, and reduce medical costs. 1 | 2020 TELEFLEX ANNUAL REPORT In addition to these measures, we continued to optimize expect it to be immediately accretive to our revenue To Our Shareholders our business and drive margin growth. We also initiated growth rates, adjusted gross and operating margin profile, a workforce reduction plan, streamlining select sales and adjusted earnings per share. The COVID-19 pandemic was the defining event and marketing functions within EMEA, as well as certain manufacturing operations within our OEM segment. Investing in the Future of 2020 for virtually every business in every We took steps to cut our operating expenses, and Innovation remains our core strength, and during 2020, market sector worldwide. Teleflex responded eliminated unnecessary discretionary spending. We will we continued to invest in products and technologies to this crisis swiftly and decisively, working to continue to tighten our belts in order to align with the that differentiate us in high-growth specialty markets provide our innovative products to hospitals, pressures of the current environment while making and offer the potential to drive revenue growth when clinicians, and patients around the globe, while select investments that will capitalize on opportunities the market recovers. We completed the roll-out of our simultaneously protecting the health and well- for long-term profitability. MANTA® Vascular Closure Device, the first commercially being of our employees.
Load more

Recommended publications
  • Rosuvastatin Calcium Patent Litigation
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE: ROSUVASTATIN CALCIUM MDL No. 08-1949-JJF PATENT LITIGATION, ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-805-JJF-LPS MYLAN PHARMACEUTICALS INC., Defendant. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-806-JJF-LPS SUN PHARMACEUTICAL INDUSTRIES LTD. , Defendant. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-807-JJF-LPS SANDOZ INC., Defendant. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-808-JJF-LPS PAR PHARMACEUTICALS INC., Defendant. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-809-JJF-LPS APOTEX CORP., Defendants. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-810-JJF-LPS AUROBINDO PHARMA LTD. AND AUROBINDO PHARMA USA INC., Defendants. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 07-811-JJF-LPS COBALT PHARMACEUTICALS INC. AND COBALT LABORATORIES INC., Defendants. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v. Civil Action No. 08-359-JJF-LPS AUROBINDO PHARMA LTD. AND AUROBINDO PHARMA USA INC., Defendants. ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs, v.
    [Show full text]
  • Complaint in Action Manufacturing Co Inc Et Al
    SDMS DocID 2037769 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA ACTION MANUFACTURING CO., INC., ALCOA INC. f/k/a ALUMINUM COMPANY OF AMERICA, ARMSTRONG WORLD INDUSTRIES, INC., CIVIL ACTION ABB INC. f/k/a FISCHER & PORTER COMPANY, NO. 02- BECKETT COMPANY, L.P., GENERAL ELECTRIC COMPANY/RCA, GENERAL MOTORS CORPORATION, HAMILTON TECHNOLOGIES, INC. (BULOVA TECHNOLOGIES, L.L.C.), HAMILTON WATCH COMPANY, INC. (SWATCH GROUP U.S., INC.), HANDY & HARMAN , HAYFORK, L.P. f7k/a HAMILTON PRECISION METALS, INC., TUBE CO., HERCULES INCORPORATED, J.W. REX, LAFRANCE CORPORATION, LUCENT TECHNOLOGIES INC., PENFLEX, INC., PLYMOUTH TUBE COMPANY, REILLY PLATING COMPANY, SIEMENS ENERGY & AUTOMATION, INC. f/k/a MOORE PRODUCTS, CO., SUNROC CORPORATION, SYNTEX (USA), INC., UNISYS CORPORATION, AND VIZ LIQUIDATION TRUST Plaintiffs, v. SIMON WRECKING COMPANY, SIMON WRECKING COMPANY, INC., SIMON RESOURCES, INC., MID-STATE TRADING COMPANY, INC., S & S INVESTMENTS, INC., SCHWAB-SIMON REALTY CORPORATION, TRENTON REALTY CORPORATION, QUAKER CITY CHEMICALS, INC., CENTRAL PENN CHEMICALS, CENTRAL PENNSYLVANIA CHEMICALS, QUAKER CITY, INC., AROOOOOI J & J SPILL SERVICE & SUPPLIES, INC., J & J TRANSPORT, INC., A & A SEPTIC SERVICE, INC., CONTINENTAL VANGUARD, INC., LIGHTMAN DRUM COMPANY, LIGHTMAN DRUM CO., INC., RESOURCE TECHNOLOGY SERVICES, INC. BISHOP TUBE CO., ELECTRALLOY CORP., MERCEGAGLIA USA, INC., AMP INCORPORATED, TYCO ELECTRONICS CORPORATION, TYCO INTERNATIONAL (US), INC., TYCO INTERNATIONAL LTD., PETROCON INC., ANTROL INDUSTRIES, INC. MCCLAPJN PLASTICS, INC., LAVELLE AIRCRAFT COMPANY, AMETEK, INC., LEEDS AND NORTHRUP COMPANY, CSS INTERNATIONAL CORP., CSS METAL FABRICATION CORPORATION, CSS MACHINE & TOOL CO., INC., ECOLOGY SYSTEMS EQUIPMENT MANUFACTURING CO., INC., TECHNITROL, INC., FBF INDUSTRIES, INC., FBF, INC., ARK PRODUCTS CO, INC., MALCO.
    [Show full text]
  • Name and Title Company and Work Address Email Phone 2020
    Executive Leadership Institute for Women 2020 Philadelphia Class List Name and Title Company and Work Address Email Phone Cigna Michele Adams 215-761-1467 1601 Chestnut Street, TL 14A [email protected] Senior Director, Accounting Policy 267-418-3629 (c) Philadelphia, PA 19192 KPMG, LLP Lauren Albertson 267-256-3183 1601 Market Street [email protected] Senior Manager 215-817-0889 (c) Philadelphia, PA 07677 KPMG, LLP Rupali Amin 267-256-3221 1601 Market Street [email protected] Managing Director 267-210-4331 (c) Philadelphia, PA 07677 KPMG, LLP Abigail (Abby) Aungst 30 North Third Street, Suite 1000 [email protected] 717-507-7707 (c) Audit Senior Manager Harrisburg, PA 17101 Aramark Kelly Banaszak 267-671-4469 1101 Market St [email protected] Director of Communications 609-760-3332 (c) Philadelphia, PA 19107 Exelon Corporation Anne Bancroft 10 S. Dearborn St [email protected] 610-812-5454 (c) Associate General Counsel Chicago, IL 60603 Aramark Jennifer Bloom 215-238-8143 1101 Market St [email protected] Finance Director 215-779-1025 (c) Philadelphia, PA 19107 Geisinger Hannah Bobrowski 570-271-5417 100 North Academy Ave, MC 28-10 [email protected] Associate Vice President, Achieving Excellence 570-926-3071 (c) Danville, PA 17822 Independence Blue Cross Roslyn Boskett 1900 Market St, 7th Floor [email protected] 856-986-9814 (c) Director, Contact Center Philadelphia, PA 19103 KPMG, LLP Kelli Brown 1601 Market Street [email protected] 610-256-0628 (c) Senior Manager Audit Philadelphia, PA 07677
    [Show full text]
  • Usef-I Q2 2021
    Units Cost Market Value U.S. EQUITY FUND-I U.S. Equities 88.35% Domestic Common Stocks 10X GENOMICS INC 5,585 868,056 1,093,655 1ST SOURCE CORP 249 9,322 11,569 2U INC 301 10,632 12,543 3D SYSTEMS CORP 128 1,079 5,116 3M CO 11,516 2,040,779 2,287,423 A O SMITH CORP 6,897 407,294 496,998 AARON'S CO INC/THE 472 8,022 15,099 ABBOTT LABORATORIES 24,799 2,007,619 2,874,948 ABBVIE INC 17,604 1,588,697 1,982,915 ABERCROMBIE & FITCH CO 1,021 19,690 47,405 ABIOMED INC 9,158 2,800,138 2,858,303 ABM INDUSTRIES INC 1,126 40,076 49,938 ACACIA RESEARCH CORP 1,223 7,498 8,267 ACADEMY SPORTS & OUTDOORS INC 1,036 35,982 42,725 ACADIA HEALTHCARE CO INC 2,181 67,154 136,858 ACADIA REALTY TRUST 1,390 24,572 30,524 ACCO BRANDS CORP 1,709 11,329 14,749 ACI WORLDWIDE INC 6,138 169,838 227,965 ACTIVISION BLIZZARD INC 13,175 839,968 1,257,422 ACUITY BRANDS INC 1,404 132,535 262,590 ACUSHNET HOLDINGS CORP 466 15,677 23,020 ADAPTHEALTH CORP 1,320 39,475 36,181 ADAPTIVE BIOTECHNOLOGIES CORP 18,687 644,897 763,551 ADDUS HOMECARE CORP 148 13,034 12,912 ADOBE INC 5,047 1,447,216 2,955,725 ADT INC 3,049 22,268 32,899 ADTALEM GLOBAL EDUCATION INC 846 31,161 30,151 ADTRAN INC 892 10,257 18,420 ADVANCE AUTO PARTS INC 216 34,544 44,310 ADVANCED DRAINAGE SYSTEMS INC 12,295 298,154 1,433,228 ADVANCED MICRO DEVICES INC 14,280 895,664 1,341,320 ADVANSIX INC 674 15,459 20,126 ADVANTAGE SOLUTIONS INC 1,279 14,497 13,800 ADVERUM BIOTECHNOLOGIES INC 1,840 7,030 6,440 AECOM 5,145 227,453 325,781 AEGLEA BIOTHERAPEUTICS INC 287 1,770 1,998 AEMETIS INC 498 6,023 5,563 AERSALE CORP
    [Show full text]
  • Wilmington Funds Holdings Template DRAFT
    Wilmington Large-Cap Strategy Fund as of 5/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS APPLE INC 4.97% MICROSOFT CORP 4.69% AMAZON.COM INC 3.45% FACEBOOK INC 1.99% ALPHABET INC 1.80% ALPHABET INC 1.77% BERKSHIRE HATHAWAY INC 1.48% JPMORGAN CHASE & CO 1.35% TESLA INC 1.20% JOHNSON & JOHNSON 1.12% UNITEDHEALTH GROUP INC 0.98% VISA INC 0.96% NVIDIA CORP 0.96% BANK OF AMERICA CORP 0.89% HOME DEPOT INC/THE 0.87% WALT DISNEY CO/THE 0.82% MASTERCARD INC 0.80% PAYPAL HOLDINGS INC 0.77% EXXON MOBIL CORP 0.68% PROCTER & GAMBLE CO/THE 0.67% COMCAST CORP 0.66% ADOBE INC 0.62% INTEL CORP 0.59% VERIZON COMMUNICATIONS INC 0.59% CISCO SYSTEMS INC 0.57% CHEVRON CORP 0.55% PFIZER INC 0.54% NETFLIX INC 0.54% AT&T INC 0.53% SALESFORCE.COM INC 0.53% ABBOTT LABORATORIES 0.51% ABBVIE INC 0.50% MERCK & CO INC 0.48% WELLS FARGO & CO 0.48% BROADCOM INC 0.47% THERMO FISHER SCIENTIFIC INC 0.47% ACCENTURE PLC 0.46% CITIGROUP INC 0.45% MCDONALD'S CORP 0.44% TEXAS INSTRUMENTS INC 0.44% COCA-COLA CO/THE 0.44% HONEYWELL INTERNATIONAL INC 0.44% LINDE PLC 0.43% MEDTRONIC PLC 0.43% NIKE INC 0.43% ELI LILLY & CO 0.42% PEPSICO INC 0.42% UNITED PARCEL SERVICE INC 0.41% WALMART INC 0.40% DANAHER CORP 0.40% UNION PACIFIC CORP 0.40% QUALCOMM INC 0.38% BRISTOL-MYERS SQUIBB CO 0.37% ORACLE CORP 0.37% LOWE'S COS INC 0.36% BLACKROCK INC 0.35% CATERPILLAR INC 0.35% AMGEN INC 0.35% BOEING CO/THE 0.35% MORGAN STANLEY 0.35% COSTCO WHOLESALE CORP 0.35% RAYTHEON TECHNOLOGIES CORP 0.34% STARBUCKS CORP 0.34% GOLDMAN SACHS GROUP INC/THE 0.34% GENERAL ELECTRIC
    [Show full text]
  • Securities and Exchange Commission Washington, D.C
    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ----------------- FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2001 Commission file number 1-1398 UGI UTILITIES, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Pennsylvania 23-1174060 (STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER IDENTIFICATION NO.) OF INCORPORATION OR ORGANIZATION) 100 Kachel Boulevard, Suite 400, Green Hills Corporate Center Reading, PA 19607 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) (610) 796-3400 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: None SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: None INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS) AND (2) HAS BEEN SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS. YES X . NO . ----- ---- Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X] At December 1, 2001 there were 26,781,785 shares of UGI Utilities Common Stock, par value $2.25 per share, outstanding, all of which were held, beneficially and of record, by UGI Corporation.
    [Show full text]
  • Ugi Utilities Inc
    UGI UTILITIES INC FORM 10-K405 (Annual Report (Regulation S-K, item 405)) Filed 12/26/1996 For Period Ending 9/30/1996 100 KACHEL BOULEVARD SUITE 400 GREEN HILLS CORPORATE Address CENTER VALLEY FORGE, Pennsylvania 19607 Telephone 610-796-3400 CIK 0000100548 Fiscal 09/30 Year SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 1996 Commission file number 1-1398 UGI UTILITIES, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Pennsylvania 23-1174060 (STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER IDENTIFICATION NO.) OF INCORPORATION OR ORGANIZATION) 100 Kachel Boulevard, Suite 400, Green Hills Corporate Center Reading, PA 19607 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) (610) 796-3400 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: None SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: None INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS) AND (2) HAS BEEN SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS. YES X . NO . Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • United States Court of Appeals for the Federal Circuit
    United States Court of Appeals for the Federal Circuit __________________________ IN RE ROSUVASTATIN CALCIUM PATENT LITIGATION __________________________ ASTRAZENECA UK LIMITED, IPR PHARMACEUTICALS INC., AND SHIONOGI SEIYAKU KABUSHIKI KAISHA, Plaintiffs-Appellees, v. AUROBINDO PHARMA LIMITED, Defendant-Appellant, AND MYLAN PHARMACEUTICALS INC., Defendant-Appellant, AND APOTEX CORP., Defendant-Appellant, AND COBALT PHARMACEUTICALS INC. AND COBALT LABORATORIES INC., Defendants-Appellants, AND SUN PHARMACEUTICAL INDUSTRIES, LTD., Defendant-Appellant, ASTRAZENECA v. AUROBINDO 2 AND TEVA PHARMACEUTICALS USA, INC., Defendant-Appellant, AND PAR PHARMACEUTICAL, INC., Defendant-Appellant, AND SANDOZ, INC., Defendant. __________________________ 2010-1460,-1461,-1462,-1463,-1464,-1465,-1466,-1467, - 1468,-1469,-1470,-1471,-1472,-1473 __________________________ Appeal from the United States District Court for the District of Delaware in case nos. 08-MD-1949, 07-CV-0810, 07-CV-0805, 07-CV-0809, 07-CV-0811, 07-CV-0806, 08-CV- 0426, and 07-CV-0808, Judge Joseph J. Farnan, Jr. ___________________________ Decided: December 14, 2012 ___________________________ CHARLES E. LIPSEY, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, of Reston, Virginia, argued for plaintiff-appellee. With him on the brief were KENNETH M. FRANKEL, and YORK M. FAULKNER. Of counsel on the brief were FORD F. FARABOW, JR., and HOWARD W. LEVINE, of Washington, DC, MARY K. FERGUSON, of Cambridge, Massa- chuettes, JOHN D. LIVINGSTONE, of Atlanta, Georgia, MARY W. BOURKE, Connolly Bove Lodge & Hutz, LLP, of Wilming- 3 ASTRAZENECA v. AUROBINDO ton, Delaware, HENRY J. RENK, Fitzpatrick, Cella, Harper & Scinto, of New York, New York, THOMAS STEVENS and JUDY YUN, AstraZeneca Pharmaceuticals, LP, of Wilmington, Delaware. ROBERT B. BREISBLATT, Katten Muchin Rosenman, LLP, of Chicago, Illinois, argued for defendant-appellant.
    [Show full text]
  • Investment Holdings As of December 31, 2019
    Investment Holdings As of December 31, 2019 Transparency of the Montana Investment Holdings The Montana Board of Investment’s holdings file is a comprehensive listing of all manager funds, separately managed and commingled, and aggregated security positions. Securities are organized across common categories: Pension Pool, Asset Class, Manager Fund, Aggregated Individual Holdings, and Non‐Pension Pools. Market values shown are in U.S. dollars. The market values shown in this document are for the individual investment holdings only and do not include any information on accounts for receivables or payables. Aggregated Individual Holdings represent securities held at our custodian bank and individual commingled accounts. The Investment Holdings Report is unaudited and may be subject to change. The audited Unified Investment Program Financial Statements will be made available once the Legislative Audit Division issues the Audit Opinion. Once issued, the Legislative Audit Division will have the Audit Opinion available online at http://leg.mt.gov/css/publications/audit/reports.asp and the complete audited financial statements will also be available on the Board’s website http://investmentmt.com/AnnualReportsAudits. Additional information can be found at www.investmentmt.com Table of Contents Consolidated Asset Pension Pool (CAPP) 4 CAPP ‐ Domestic Equities 5 CAPP – Core Fixed Income 24 CAPP ‐ International Equities 29 CAPP ‐ Private Equities 45 CAPP ‐ Real Estate 48 CAPP ‐ Natural Resources 50 CAPP – Non Core Fixed Income 52 CAPP ‐ Cash 62 Short
    [Show full text]
  • Look Who Said Goodbye to the U.S.A
    LOOK WHO SAID GOODBYE TO THE U.S.A. Here is a list of companies we've confirmed are "Exporting America." These are U.S. companies either sending American jobs overseas, or choosing to employ cheap overseas labor, instead of American workers. 3Com B Continued… 3M Bechtel BellSouth A Best Buy Accenture Black & Decker Adaptec BMC Software ADC Boeing Adobe Systems Brocade Advanced Energy Industries Bumble Bee Aetna Affiliated Computer Services C A.G. Edwards Cadence Design Systems Agere Systems Capital One Agilent Tech. Carrier AIG Cendant Alamo Rent A Car Cerner Corporation Albertson's Charles Schwab Allen Systems Group ChevronTexaco Alliance Semiconductor CIBER Allstate Ciena Alpha Thought Global Cigna Amazon.com Circuit City, Inc. AMD Cisco Systems American Express Citigroup American Household CNA American Management Systems Coca-Cola American Standard Cognizant Technology Solutions Amphenol Corp. Columbia House Analog Devices Comcast Holdings Andrew Corp. Computer Associates Anheuser-Busch Computer Sciences Corporation AOL CompuServe Apple Continental Airlines Applied Materials Convergys A.T. Cross Company Cooper Tire & Rubber AT&T Cooper Tools AT&T Wireless Countrywide Financial A.T. Kearney COVAD Comm. Automatic Data Processing CSX Avanade Cummins Avery Dennison Cypress Semiconductor B D Bank of America Dana Corporation Bank of New York Delco Remy Bank One Dell Computer BearingPoint Delphi Bear Stearns Delta Air Lines D Continued…. H Continued…. Direct TV Humana Discover Document Sciences Corp. I Dow Chemical IBM Dun & Bradstreet iGate
    [Show full text]
  • New Covenant Growth Fund
    SCHEDULE OF INVESTMENTS (Unaudited) March 31, 2020 New Covenant Growth Fund Market Value Market Value Description Shares ($ Thousands) Description Shares ($ Thousands) COMMON STOCK — 96.0% COMMON STOCK (continued) Bosnia and Herzegovina — 0.0% IMAX * 2,244 $ 20 RenaissanceRe Holdings Ltd. 248 $ 37 Intelsat * 8,389 13 – Interpublic Group of Cos Inc/The 8,487 137 Canada — 0.1% Iridium Communications * 366 8 Lululemon Athletica Inc * 1,014 192 – John Wiley & Sons Inc, Cl A 236 9 Cayman Islands — 0.0% Liberty Broadband, Cl A * 113 12 Herbalife * 1,088 31 Lions Gate Entertainment, Cl A * 7,278 44 – Ireland — 1.0% Live Nation Entertainment Inc * 181 8 Accenture PLC, Cl A 11,297 1,844 Match Group * 703 46 Jazz Pharmaceuticals PLC * 616 62 Meredith 1,401 17 Mallinckrodt * 13,812 27 MSG Networks * 2,988 31 Medtronic PLC 19,976 1,801 New York Times, Cl A 1,515 47 NortonLifeLock 13,065 245 Nexstar Media Group, Cl A 455 26 Perrigo Co PLC 211 10 Omnicom Group Inc 10,137 557 Scholastic 1,266 32 3,989 – Shenandoah Telecommunications 1,286 63 Puerto Rico — 0.0% Sirius XM Holdings 7,153 35 Popular Inc 1,507 53 – Spotify Technology SA * 608 74 Switzerland — 0.0% Sprint Corp * 2,200 19 Garmin Ltd 1,092 82 Take-Two Interactive Software Inc * 830 98 – TechTarget * 1,986 41 United Kingdom — 0.2% TEGNA 3,052 33 Aon PLC 2,921 482 T-Mobile US Inc * 2,824 237 Healthpeak Properties 9,384 224 Twitter Inc * 7,369 181 706 – Verizon Communications Inc 62,462 3,356 United States — 94.7% ViacomCBS, Cl B 1,000 14 Communication Services — 8.3% Walt Disney Co/The 26,709
    [Show full text]
  • Triumph Group Annual Report 2020
    Triumph Group Annual Report 2020 Form 10-K (NYSE:TGI) Published: May 28th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-12235 Triumph Group, Inc. (Exact name of registrant as specified in its charter) Delaware 51-0347963 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 899 Cassatt Road, Suite 210, Berwyn, Pennsylvania 19312 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (610) 251-1000 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 per share TGI New York Stock Exchange Purchase rights New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]